Fig 3. Clinical response durations after rituximab maintenance therapy, within 36 months follow-up.

In panel A, response durations within the three years (156 weeks) follow-up are shown, for 14 major responders and four moderate responders. In panel B, time points for start of clinical responses are shown, for major and moderate responders. In both panels A and B, the 11 red dots denote patients with still ongoing clinical response at 156 weeks (end of study), while the 7 black squares denote patients experiencing partial or full relapse during the 36 months follow-up period. The overall response criterion was a Fatigue score ≥ 4.5 for a minimum of six consecutive weeks, which must include at least one recording of Fatigue score > 5.0 during the response period. Single response periods and the sum of response periods during follow-up were recorded as response duration.